Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness

Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness

Triple ISO Certification Recognition Positions Company as a Standard-Bearer in Clinical Decision Support Quality Infrastructure

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced that Seegnal eHealth Ltd., its Israeli operating subsidiary, has been granted the prestigious Gold Mark by the Standards Institution of Israel, a high institutional quality distinction awarded to organizations that have embedded a culture of excellence across their management systems, processes, and product lifecycle. The Gold Mark certification further solidifies Seegnal's commercialization-readiness and its standing as an enterprise-grade platform trusted by leading healthcare systems.

A Landmark Recognition in Quality Leadership
The Gold Mark is conferred exclusively upon organizations that have adopted quality and excellence as a foundational organizational ethos, not merely as a compliance exercise, and that simultaneously hold three or more quality certification marks attesting to the alignment of their management systems, processes, and products with Israeli and international standards. It represents the intersection of institutional rigor, operational discipline, and an unwavering commitment to safety and performance.

Seegnal eHealth Ltd. received the Gold Mark in recognition of holding all three of the following certification marks, each issued by the Standards Institution of Israel:

  • ISO 13485:2016: Medical Devices Quality Management Systems, certifying that Seegnal's quality management processes meet the most demanding international standards applicable to medical device manufacturers and suppliers;
  • ISO 27799: Information Security Management in Health, confirming that Seegnal's data governance and information security architecture conform to sector-specific requirements for the handling of sensitive health data; and
  • ISO 27001:2022: Information Security Management Systems (ISMS), attesting to a certified and independently audited information security management framework across the organization.

The Gold Mark certificate for 2026 was signed by Dr. Gilad Golub, CEO of the Standards Institution of Israel, and Avital Weinberg, VP of the Quality & Certification Division.

About Seegnal Inc.
Seegnal Inc. (TSXV: SEGN) is a global leader in clinical decision support, applying patient-centric medication safety standards to improve outcomes across healthcare systems. Seegnal's proprietary platform is deployed at leading hospital networks and provides real-time, point-of-care medication safety intelligence. For more information, visit www.seegnal.com.

Contact Information
Elad Bibi-Aviv
Chief Executive Officer
+1 (929) 248 4652
Arx Investor Relations
North American Equities Desk
seegnal@arxhq.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Source

SEGN:CA
The Conversation (0)
BriaCell Therapeutics (TSX:BCT)

BriaCell's Cell-Based ‘Melanoma’ Enters the Skin Cancer Vaccine Conversation

Clinical-stage immuno-oncology company BriaCell Therapeutics (TSX:BCT,NASDAQ:BCTX) has achieved a “key genetic engineering milestone” with ‘Melanoma’, its personalized whole-cell melanoma immunotherapy vaccine candidate.The achievement allows the vaccine’s program to proceed towards clinical... Keep Reading...
Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received... Keep Reading...
DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

(TheNewswire) Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the... Keep Reading...
DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0... Keep Reading...
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2026

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind,... Keep Reading...
Lexaria Enters a Material Transfer Agreement With PegBio

Lexaria Enters a Material Transfer Agreement With PegBio

KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement ("MTA") with Pegbio Co., Ltd ("PegBio") to investigate Lexaria's... Keep Reading...

Interactive Chart

Latest Press Releases

Related News